These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19497744)

  • 1. Identification of a beta3-peptide HIV fusion inhibitor with improved potency in live cells.
    Bautista AD; Stephens OM; Wang L; Domaoal RA; Anderson KS; Schepartz A
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3736-8. PubMed ID: 19497744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of HIV-1 fusion inhibitors targeting gp41.
    Lu K; Asyifah MR; Shao F; Zhang D
    Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Evaluation of Fluorination as Modification for Peptide-Based Fusion Inhibitors against HIV-1 Infection.
    Huhmann S; Nyakatura EK; Rohrhofer A; Moschner J; Schmidt B; Eichler J; Roth C; Koksch B
    Chembiochem; 2021 Dec; 22(24):3443-3451. PubMed ID: 34605595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting HIV fusion with a beta-peptide foldamer.
    Stephens OM; Kim S; Welch BD; Hodsdon ME; Kay MS; Schepartz A
    J Am Chem Soc; 2005 Sep; 127(38):13126-7. PubMed ID: 16173723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-Specific Polymer Attachment to HR2 Peptide Fusion Inhibitors against HIV-1 Decreases Binding Association Rates and Dissociation Rates Rather Than Binding Affinity.
    Danial M; Stauffer AN; Wurm FR; Root MJ; Klok HA
    Bioconjug Chem; 2017 Mar; 28(3):701-712. PubMed ID: 27737540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.
    Chong H; Yao X; Qiu Z; Sun J; Zhang M; Waltersperger S; Wang M; Liu SL; Cui S; He Y
    FASEB J; 2013 Mar; 27(3):1203-13. PubMed ID: 23233535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41.
    Jiang X; Jia Q; Lu L; Yu F; Zheng J; Shi W; Cai L; Jiang S; Liu K
    Amino Acids; 2016 Dec; 48(12):2867-2873. PubMed ID: 27631437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An effective conjugation strategy for designing short peptide-based HIV-1 fusion inhibitors.
    Liang G; Wang H; Chong H; Cheng S; Jiang X; He Y; Wang C; Liu K
    Org Biomol Chem; 2016 Aug; 14(33):7875-82. PubMed ID: 27454320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41.
    Cai L; Jiang S
    ChemMedChem; 2010 Nov; 5(11):1813-24. PubMed ID: 20845360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The current progress in the development of HIV-1 fusion inhibitors].
    Shi WG; Jia QY; Liu KL
    Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion.
    Melikyan GB; Egelhofer M; von Laer D
    J Virol; 2006 Apr; 80(7):3249-58. PubMed ID: 16537592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 gp41: mediator of fusion and target for inhibition.
    Weiss CD
    AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
    Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
    ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
    [No Abstract]   [Full Text] [Related]  

  • 14. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
    Cai L; Gochin M; Liu K
    Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.
    Zhuang M; Wang W; De Feo CJ; Vassell R; Weiss CD
    J Biol Chem; 2012 Mar; 287(11):8297-309. PubMed ID: 22235115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
    Yi HA; Fochtman BC; Rizzo RC; Jacobs A
    Curr HIV Res; 2016; 14(3):283-94. PubMed ID: 26957202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41.
    Jiang S; Tala SR; Lu H; Zou P; Avan I; Ibrahim TS; Abo-Dya NE; Abdelmajeid A; Debnath AK; Katritzky AR
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6895-8. PubMed ID: 21978673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.
    Xu W; Pu J; Su S; Hua C; Su X; Wang Q; Jiang S; Lu L
    AIDS; 2019 Aug; 33(10):1545-1555. PubMed ID: 30932963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
    Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
    Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.